Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney V Fletcher

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
BMC Complementary Medicine and Therapies|April 10, 2021
In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4<sup>+</sup> T-cell activation/ exhaustionOmalla A Olwenyi, Bannet Asingura, Prossy Naluyima, et al.
Scientific Reports|May 10, 2024
In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cellsSean N Avedissian, Johid R Malik, Anthony T Podany, et al.
Frontiers in Pharmacology|August 20, 2016
Etravirine Pharmacokinetics in HIV-Infected Pregnant WomenNikki Mulligan, Stein Schalkwijk, Brookie M Best, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Current Protocols|June 10, 2024
Establishment of a Four-Cell In Vitro Blood-Brain Barrier Model With Human Primary Brain CellsJohid R Malik, Ukamaka O Modebelu, Courtney V Fletcher, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
The Journal of Infectious Diseases|March 13, 2018
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ARTMonica Gandhi, Rajesh T Gandhi, Andrei Stefanescu, et al.
Antiviral Research|April 10, 2018
Adipocytes impair efficacy of antiretroviral therapyJacob Couturier, Lee C Winchester, James W Suliburk, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissuesCourtney V Fletcher, Kathryn Staskus, Stephen W Wietgrefe, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
BMC Complementary Medicine and Therapies|April 10, 2021
In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4<sup>+</sup> T-cell activation/ exhaustionOmalla A Olwenyi, Bannet Asingura, Prossy Naluyima, et al.
Scientific Reports|May 10, 2024
In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cellsSean N Avedissian, Johid R Malik, Anthony T Podany, et al.
Frontiers in Pharmacology|August 20, 2016
Etravirine Pharmacokinetics in HIV-Infected Pregnant WomenNikki Mulligan, Stein Schalkwijk, Brookie M Best, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Current Protocols|June 10, 2024
Establishment of a Four-Cell In Vitro Blood-Brain Barrier Model With Human Primary Brain CellsJohid R Malik, Ukamaka O Modebelu, Courtney V Fletcher, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
The Journal of Infectious Diseases|March 13, 2018
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ARTMonica Gandhi, Rajesh T Gandhi, Andrei Stefanescu, et al.
Antiviral Research|April 10, 2018
Adipocytes impair efficacy of antiretroviral therapyJacob Couturier, Lee C Winchester, James W Suliburk, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissuesCourtney V Fletcher, Kathryn Staskus, Stephen W Wietgrefe, et al.
Pageof 17